Advice
in the absence of a submission from the holder of the marketing authorisation
certolizumab pegol (Cimzia®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- certolizumab pegol (Cimzia)
- SMC ID:
- 1155/16
- Indication:
- Treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 May 2016